“The conscience of the city.” That’s how Victor Hugo described the sewers of Paris.
One and a half centuries later, the wastewater running under the streets might also have become a lifesaver. Indeed, it could turn out to be our greatest ally in the battle against Covid-19 and future pandemics.
Sewers have always contained vital information on viruses. But the persistent problem facing environmental virologists is that they have lacked the technology to unlock the most important data. That’s no longer the case.
Drawing on an arsenal of sophisticated water analysis technologies, public health experts can now detect tiny strands of the disease in wastewater. Which means it is now possible to estimate the concentration of the virus among the population at a very localised level.
Such information is vital. It can help governments track the progress of the disease, spot fresh waves in the very early stages and, ultimately, limit its spread through targeted measures such as lockdowns.
This could be revolutionary in containing pandemics.
Progress so far has been encouraging. Scientists have identified fragments of the virus’s genetic material (RNA) in sewage and have proved that these are correlated with local infection rates. The RNA can be detected within three days of infection. That’s crucial when it comes to Covid-19. In humans, physical symptoms typically take five to 14 days to appear. In fact, a large proportion of carriers (as high as 80 per cent, according to some studies) show very mild symptoms or none at all and could thus be inadvertent spreaders.
Data so far suggests that viral RNA in wastewater can be identified at least five to six days earlier than people experience physical symptoms. That is a big window – research from Columbia University suggests that the death toll in US could have been lower by as much as 36,000 if the country had started imposing social distancing measures just one week earlier than it did.1
In Switzerland, researchers from Ecole Polytechnique Federale de Lausanne (EPFL) and Swiss Federal Institute of Aquatic Science and Technology (EAWAG) are testing samples from 12 wastewater treatment plants which together serve some 800,000 inhabitants.
The results are impressively granular – they have been able to spot the infection in February samples from Lugano and Zurich, when the cities respectively had only one and six known cases. The eventual aim, the scientists say, is to develop an early warning system – both for any future waves of the coronavirus and for other viruses.
Researchers at Arizona State University’s Human Health Observatory (HHO), who have been tracking health indicators in sewage for more than a decade, believe that techniques can be refined further to make it possible to identify a single infected individual among 2 million people.
To achieve this, it’s necessary to establish an accurate estimate of how much RNA material is produced by an individual, as well as to factor in the degradation rates and to adjust for the profile of each community (such as variations in water consumption).
The scale of the research – tests and analysis span not only the US and Switzerland, but also the UK, France, The Netherlands, New Zealand, Australia and beyond – gives hope that progress will be rapid.
For water companies developing such tech, the commercial opportunities could be considerable. Already, firms such as American Water Works are joining forces with scientists in the quest for an early warning system for the re-emergence of Covid-19.
Meanwhile, companies that manufacture molecular testing equipment such as Danaher and Thermo Fisher, also have a major role to play.2 US-based wastewater-testing startup Biobot Analytics, whose projects include Covid-19 tests, recently raised an additional USD4.2 million in seed funding.
Once scientists perfect analysis techniques, their use could broaden beyond virus spotting and tracking. Wastewater also holds vital information on the use of antibiotics and other legal and illegal drugs, hormones, pesticides and even x-rays.
Such data can be harnessed for early intervention in drug abuse, targeted promotion of healthier lifestyles, improving farming practices and more.
The generation and analysis of big data from water and sewage could become a defining feature of the industry in the coming years, offering another line of defence against health threats and giving rise to a new range of water investment opportunities.
[1] “Differential Effects of Intervention Timing on COVID-19 Spread in the United States,” by Sen Pei, Sasikiran Kandula and Jeffrey Shaman, Columbia University
[2] American Water Works, Danaher and Thermo Fisher are part of the Pictet-Water portfolio.
This marketing material is issued by Pictet Asset Management (Europe) S.A.. It is neither directed to, nor intended for distribution or use by, any person or entity who is a citizen or resident of, or domiciled or located in, any locality, state, country or jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation. The latest version of the fund‘s prospectus, Pre-Contractual Template (PCT) when applicable, Key Investor Information Document (KIID), annual and semi-annual reports must be read before investing. They are available free of charge in English on www.assetmanagement.pictet or in paper copy at Pictet Asset Management (Europe) S.A., 15 avenue J.F. Kennedy, L-1855 Luxembourg, or at the office of the fund local agent, distributor or centralizing agent if any. The KIID is also available in the local language of each country where the compartment is registered. The prospectus, the PCT when applicable, and the annual and semi-annual reports may also be available in other languages, please refer to the website for other available languages. Only the latest version of these documents may be relied upon as the basis for investment decisions.
The summary of investor rights (in English and in the different languages of our website) is available here and at www.assetmanagement.pictet under the heading "Resources", at the bottom of the page.
The list of countries where the fund is registered can be obtained at all times from Pictet Asset Management (Europe) S.A., which may decide to terminate the arrangements made for the marketing of the fund or compartments of the fund in any given country.
The information and data presented in this document are not to be considered as an offer or solicitation to buy, sell or subscribe to any securities or financial instruments or services.
Information, opinions and estimates contained in this document reflect a judgment at the original date of publication and are subject to change without notice. Pictet Asset Management (Europe) S.A. has not taken any steps to ensure that the securities referred to in this document are suitable for any particular investor and this document is not to be relied upon in substitution for the exercise of independent judgment. Tax treatment depends on the individual circumstances of each investor and may be subject to change in the future. Before making any investment decision, investors are recommended to ascertain if this investment is suitable for them in light of their financial knowledge and experience, investment goals and financial situation, or to obtain specific advice from an industry professional.
The value and income of any of the securities or financial instruments mentioned in this document may fall as well as rise and, as a consequence, investors may receive back less than originally invested.
The investment guidelines are internal guidelines which are subject to change at any time and without any notice within the limits of the fund's prospectus.
The mentioned financial instruments are provided for illustrative purposes only and shall not be considered as a direct offering, investment recommendation or investment advice. Reference to a specific security is not a recommendation to buy or sell that security. Effective allocations are subject to change and may have changed since the date of the marketing material.
Past performance is not a guarantee or a reliable indicator of future performance. Performance data does not include the commissions and fees charged at the time of subscribing for or redeeming shares.
Any index data referenced herein remains the property of the Data Vendor. Data Vendor Disclaimers are available on assetmanagement.pictet in the “Resources” section of the footer.
This document is a marketing communication issued by Pictet Asset Management and is not in scope for any MiFID II/MiFIR requirements specifically related to investment research. This material does not contain sufficient information to support an investment decision and it should not be relied upon by you in evaluating the merits of investing in any products or services offered or distributed by Pictet Asset Management.
Pictet AM has not acquired any rights or license to reproduce the trademarks, logos or images set out in this document except that it holds the rights to use any entity of the Pictet group trademarks. For illustrative purposes only.